• Vaccine Name: RHDV VLP VP60 Vaccine
• Target Pathogen: Rabbit hemorrhagic disease virus
• Target Disease: Rabbit hemorrhagic disease
• Type: Virus-Like Particle Vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: VP60 (Zheng et al., 2016)
• Preparation: RHDV VLPs were autonomously assembled in the silkworm pupae that have been infected by rBmNPV-VP60 (Zheng et al., 2016)
• Immunization Route: Intramuscular injection (i.m.)
• Description: VLP-based vaccine developed from silkworm pupae confers protection against rabbit hemorrhagic disease virus in rabbits. (Zheng et al., 2016)

Rabbit Response

• Vaccination Protocol: Ninety rabbits were randomly divided into 3 groups (n = 30) and inoculated i.m. with 1 ml VLPs emulsified in Freund's Complete Adju- vant (FCA) (HAU of VLPs = 10^4), an equal dose of VLPs alone, or a mock control. (Zheng et al., 2016)
• Immune Response: Detectable HI titers in animals immunized with VLPs with or without FCA were first detected at 15 days after vaccination, and reached a plateau of 2^10 and 2^8 reciprocal dilutions by 90 and 60 days after vaccination, respectively. (Zheng et al., 2016)
• Challenge Protocol: At 30, 180, 240, and 360 days after vaccination, 6 rabbits from each group were randomly selected and challenged i.m. with 100 × LD50 of live RHDV (CHA/JL/10 strain) (Zheng et al., 2016)
• Efficacy: Full survival was observed in VLP + FCA rabbits when challenged at 360 days after vaccination with a single i.m. injection of 100 × LD50 RHDV. Full survival was observed in VLP only rabbits when challenged at 180 days after vaccination. In contrast, all control animals died 24–96 h after RHDV challenge with symptoms typical of RHD. (Zheng et al., 2016)